PPM - Cytogenomic Analysis of Newly Diagnosed Plasma Cell Disorders (Multiple Myeloma, MGUS, Plasmacytoma, Smoldering Myeloma)-Description and References

Description and References

Pdf Summary

This document provides an overview of new recommendations for laboratory cytogenomic work-up of patients with newly diagnosed plasma cell disorders, including multiple myeloma (MM), monoclonal gammopathy of unknown significance (MGUS), plasmacytoma, and smoldering myeloma (SMM). The module instructs laboratory directors to choose 10 consecutive cases of new plasma cell disorders and answer questions regarding the work-up of each case.<br /><br />The learning objectives of the module are to implement newly developed practice guidelines and seminal publications to improve diagnosis, treatment, and outcomes for patients newly diagnosed with plasma cell disorders.<br /><br />Multiple myeloma is a malignant proliferation of monoclonal plasma cells, and different genetic subtypes of the disease have been identified. MM, MGUS, and SMM are different stages of the disease with varying outcomes. Diagnostic criteria and guidelines for investigation of suspected MM have been developed by the International Myeloma Working Group (IMWG) and International Myeloma Workshop.<br /><br />Cytogenetic abnormalities play a role in the prognosis and choice of therapy for high-risk MM patients. Hyperdiploidy with multiple trisomies and translocations involving the IGH gene are two major genetic events implicated in the development of myeloma cells. Recent studies have shown that different genomic alterations can coexist in mixed subclones.<br /><br />The document includes references to relevant studies and guidelines for further information.<br /><br />In summary, this document provides an overview of the cytogenomic analysis of newly diagnosed plasma cell disorders. It emphasizes the importance of implementing new practice guidelines to improve the diagnosis, treatment, and outcomes for patients with these disorders. The document highlights the genetic subtypes of multiple myeloma and the role of cytogenetic abnormalities in determining prognosis and therapy choices.

Keywords

laboratory cytogenomic work-up

plasma cell disorders

multiple myeloma

monoclonal gammopathy of unknown significance

plasmacytoma

smoldering myeloma

practice guidelines

diagnosis

treatment

outcomes